

# **Horizon scanning for new & emerging health technologies**

---

**Dr Ali Cook**  
**Associate Director**  
**National Horizon Scanning Centre**  
**University of Birmingham**

**ABCD Spring Meeting**  
**Thursday 6<sup>th</sup> April, 2006**



# National Horizon Scanning Centre

---

**Provides advance notice to the Department of Health and wider NHS of significant new and emerging technologies up to 3 years before launch, that need:**

- **consideration of clinical and cost effectiveness**
- **consideration of cost impact, or**
- **further evaluation**



# Topic selection - remit

---

Health technology not yet adopted by a health care system


- **pharmaceuticals**

  - phase II or III trials or pre-launch

- **medical devices, diagnostics and interventions**

  - prior to, or within 6 months of marketing or marketed but <10% diffused or localised to a few centres

# NHSC – Identification sources






# Prioritisation criteria

---

- **Innovation for the patient group**

**And one or more of:**

- **significant patient group size and mortality & morbidity**
- **potential for additional clinical benefit**
- **potential for major resource implications**
- **major service re-organisation or training**
- **inappropriate speed of adoption**



# Main Output - technology briefings

---

## ■ Information

- technology, marketing plans and timing
- patient indications, patient group size, epidemiology
- current treatment, service usage
- current guidance and guidelines
- research evidence and ongoing research

## ■ Sources

- commercial developer or research teams
- routine data – deaths, hospital stays, operations, drugs
- research abstracts and publications
- patient groups
- **clinical experts (includes possible future impact)**



# NHSC Customers

---

- DH policy teams
- NICE
- Centre for Evidence-Based Purchasing (CEP)
- Interventional Procedures Programme (IPP) at NICE
- National Screening Committee
- HTA programme
- Rapid review panel (HPA)




# NHSC and Diabetes

---

## Topics have included:

- **2006: t+ diabetes**
- **2005: Vildagliptin, Muraglitazar, Tesaglitazar**
- **2003: Exenatide, Ruboxistaurin**
- **2000: Insulin glargine**
- **1998: Rosiglitazone, Pioglitazone,  
Inhaled insulin**



# NHSC & the ABCD

---

## Two areas for future collaboration:

- PRIORITISATION of technologies the NHSC has already identified
- INDENTIFICATION of new technologies for the NHSC to consider



# Prioritisation – every 2 years

---

February 2006 – technology list (n=17) sent to four ABCD members for prioritisation.

Aim is to:

- Filter out – established; unlikely to develop or diffuse within the NHS; trivial or minor advances
- Identify high priority – significant impact & likely timescale of impact




# Identification – as and when

---

Spring 2006 – forms to be developed for members to suggest new **high priority** technologies to the NHSC that may have a significant impact on the NHS or patients in the future.

- new (in early diffusion)
- emerging (usually not licensed or launched)
- represent a change in indication or use of an existing technology
- are part of a group of developing technologies that, as a whole, may be significant.



# Contact details

---

**Dr Ali Cook**

**a.m.cook@bham.ac.uk**

**☎ 0121 414 8186**

**[www.pcpoh.bham.ac.uk/publichealth/horizon](http://www.pcpoh.bham.ac.uk/publichealth/horizon)**